VEGFA and acute lymphoblastic leukemia: Although the prediction interval for the pooled effect size includes zero, indicating variability in effect sizes across studies—potentially due to differences in patient populations, study designs, or methodological approaches—the statistically significant pooled SMD of 0.878 (95% CI: 0.276–1.479; p = 0.004), along with the consistent outcomes observed in the sensitivity analyses (Section 3.5), reinforces the reliability of the association between elevated VEGF‐A levels and poor prognosis in ALL.